Show simple item record

dc.contributor.authorHarris, Maggie A
dc.contributor.authorRadford, John A
dc.contributor.authorDeakin, David P
dc.contributor.authorJames, Roger D
dc.contributor.authorSwindell, Ric
dc.contributor.authorCowan, Richard A
dc.date.accessioned2009-08-20T11:53:34Z
dc.date.available2009-08-20T11:53:34Z
dc.date.issued2004-02
dc.identifier.citationLimited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma. 2004, 16 (1):53-7 Clin Oncolen
dc.identifier.issn0936-6555
dc.identifier.pmid14768756
dc.identifier.urihttp://hdl.handle.net/10541/78006
dc.description.abstractAIMS: To analyse the treatment outcome for patients with stage I and II infra-diaphragmatic Hodgkin's lymphoma. MATERIALS AND METHODS: A retrospective review of case notes for 33 consecutive patients treated between 1988 and 2000. Twenty-five out of 33 patients received radiotherapy alone, three out of 33 patients received minimal initial chemotherapy (MIT) (4 weeks VAPEC B) and five patients received six cycles of ChlVPP EVA hybrid chemotherapy before radiotherapy. Radiotherapy was given as a limited field in 32 out of 33 patients. RESULTS: Twenty-seven out of 33 patients were men (82%), and the median age was 47 years. Fifteen of the 33 patients were stage IA, 15 were IIA, 1 was IB and 2 were IIB. The median follow-up was 71 months. Histological subtype was lymphocyte predominant (15/33), nodular sclerosis (11/33), mixed cellularity (4/33), lymphocyte-rich classical (1/33) and unclassifiable (2/33). The 5-year overall survival was 89% and 5-year relapse-free survival was 85%. The median time to relapse was 37 months (range 7-65 months). One out of five relapses was within the previous radiotherapy field. All five relapses had received radiotherapy alone and four were salvaged with chemotherapy. There have been four second malignancies and one patient transformed to high-grade non-Hodgkin's lymphoma. No patient has died of Hodgkin's lymphoma. CONCLUSIONS: In our cohort of patients with infra-diaphragmatic stage I and II Hodgkin's lymphoma treated with limited-field radiotherapy, no patients died from uncontrolled disease. The use of MIT may reduce the risk of relapse and obviate the need for conventional salvage chemotherapy. Late relapses may occur, and second malignancies are a cause for concern underlining the need for long-term follow-up.
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBleomycin
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshChlorambucil
dc.subject.meshCyclophosphamide
dc.subject.meshDisease-Free Survival
dc.subject.meshDoxorubicin
dc.subject.meshEtoposide
dc.subject.meshFemale
dc.subject.meshHodgkin Disease
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshPrednisolone
dc.subject.meshProcarbazine
dc.subject.meshRetrospective Studies
dc.subject.meshVinblastine
dc.subject.meshVincristine
dc.titleLimited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. maggieharris@chorlton60.freeserve.co.uken
dc.identifier.journalClinical Oncologyen
html.description.abstractAIMS: To analyse the treatment outcome for patients with stage I and II infra-diaphragmatic Hodgkin's lymphoma. MATERIALS AND METHODS: A retrospective review of case notes for 33 consecutive patients treated between 1988 and 2000. Twenty-five out of 33 patients received radiotherapy alone, three out of 33 patients received minimal initial chemotherapy (MIT) (4 weeks VAPEC B) and five patients received six cycles of ChlVPP EVA hybrid chemotherapy before radiotherapy. Radiotherapy was given as a limited field in 32 out of 33 patients. RESULTS: Twenty-seven out of 33 patients were men (82%), and the median age was 47 years. Fifteen of the 33 patients were stage IA, 15 were IIA, 1 was IB and 2 were IIB. The median follow-up was 71 months. Histological subtype was lymphocyte predominant (15/33), nodular sclerosis (11/33), mixed cellularity (4/33), lymphocyte-rich classical (1/33) and unclassifiable (2/33). The 5-year overall survival was 89% and 5-year relapse-free survival was 85%. The median time to relapse was 37 months (range 7-65 months). One out of five relapses was within the previous radiotherapy field. All five relapses had received radiotherapy alone and four were salvaged with chemotherapy. There have been four second malignancies and one patient transformed to high-grade non-Hodgkin's lymphoma. No patient has died of Hodgkin's lymphoma. CONCLUSIONS: In our cohort of patients with infra-diaphragmatic stage I and II Hodgkin's lymphoma treated with limited-field radiotherapy, no patients died from uncontrolled disease. The use of MIT may reduce the risk of relapse and obviate the need for conventional salvage chemotherapy. Late relapses may occur, and second malignancies are a cause for concern underlining the need for long-term follow-up.


This item appears in the following Collection(s)

Show simple item record